Failure of annexin-based apoptosis imaging in the assessment of antiangiogenic therapy effects

EJNMMI Research

Volumn 1, Issue 1, 2011, Pages 1-10

  Lederle, Wiltrud ^a   Arns, Susanne ^a   Rix, Anne ^a   Gremse, Felix ^a   Doleschel, Dennis ^a   Schmaljohann, Jörn ^a   Mottaghy, Felix M ^a,b   Kiessling, Fabian ^a   Palmowski, Moritz ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Apoptosis; Optical imaging; Therapy monitoring; Ultrasound

Indexed keywords

DNA NUCLEOTIDYLEXOTRANSFERASE; SUNITINIB; TECHNETIUM 6 HYDRAZINONICOTINIC ANNEXIN V TC 99M; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NICK END LABELING; NONHUMAN; OPTICAL TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THREE DIMENSIONAL IMAGING; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 84863960345     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-1-26     Document Type: Article

References (27)

1. Lahorte CM, Vanderheyden JL, Steinmetz N, Van de WC, Dierckx RA, Slegers G: Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004, 31:887-919.
2. Blankenberg FG: In vivo detection of apoptosis. J Nucl Med 2008, 49(Suppl 2):81S-95S.
3. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, Kopiwoda S, Abrams MJ, Drakes M, Robbins RC, Maecker HT, Strauss HW: In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998, 95:6349-6354.
4. De Saint-Hubert M, Prinsen K, Mortelmans L, Verbruggen A, Mottaghy FM: Molecular imaging of cell death. Methods 2009, 48:178-187.
5. De Saint-Hubert M, Mottaghy FM, Vunckx K, Nuyts J, Fonge H, Prinsen K, Stroobants S, Mortelmans L, Deckers N, Hofstra L, Reutelingsperger CP, Verbruggen A, Rattat D: Site-specific labeling of 'second generation' annexin V with 99 mTc(CO)3 for improved imaging of apoptosis in vivo. Bioorg Med Chem 2010, 18:1356-1363.
6. Bauwens M, De Saint-Hubert M, Devos E, Deckers N, Reutelingsperger C, Mortelmans L, Himmelreich U, Mottaghy FM, Verbruggen A: Site-specific 68Ga-labeled Annexin A5 as a PET imaging agent for apoptosis. Nucl Med Biol 2011, 38:381-392.
7. Petrovsky A, Schellenberger E, Josephson L, Weissleder R, Bogdanov A Jr: Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res 2003, 63:1936-1942.
8. Schellenberger EA, Bogdanov A Jr, Hogemann D, Tait J, Weissleder R, Josephson L: Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Mol Imaging 2002, 1:102-107.
9. Krishnan AS, Neves AA, de Backer MM, Hu DE, Davletov B, Kettunen MI, Brindle KM: Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology 2008, 246:854-862.
10. Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, Fitzpatrick JM, Raghunath PN, Tomaszewski JE, Kelly C, Steinmetz N, Green A, Tait JF, Leppo J, Blankenberg FG, Jain D, Strauss HW: Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001, 7:1347-1352.
11. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, Rigo P, Green A: Increased uptake of the apoptosis-imaging agent (99 m) Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002, 8:2766-2774.
12. Schellenberger EA, Bogdanov A Jr, Petrovsky A, Ntziachristos V, Weissleder R, Josephson L: Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy. Neoplasia 2003, 5:187-192.
13. Choi HK, Yessayan D, Choi HJ, Schellenberger E, Bogdanov A, Josephson L, Weissleder R, Ntziachristos V: Quantitative analysis of chemotherapeutic effects in tumors using in vivo staining and correlative histology. Cell Oncol 2005, 27:183-190.
14. Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, Shah C, McKinley ET, Xie J, Mutic NJ, Washington MK, LaFleur B, Tantawy MN, Peterson TE, Ansari MS, Baldwin RM, Rothenberg ML, Bornhop DJ, Gore JC, Coffey RJ: Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 2008, 14:7413-7422.
15. Palmowski M, Huppert J, Hauff P, Reinhardt M, Schreiner K, Socher MA, Hallscheidt P, Kauffmann GW, Semmler W, Kiessling F: Vessel fractions in tumor xenografts depicted by flow-or contrast-sensitive threedimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res 2008, 68:7042-7049.
16. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
17. Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, Zentgraf H, Bock M, Eisenhut M, Semmler W, Kiessling F: Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007, 67:1555-1562.
18. Palmowski M, Lederle W, Gaetjens J, Socher M, Hauff P, Bzyl J, Semmler W, Gunther RW, Kiessling F: Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound. Eur J Radiol 2010, 75:e149-e153.
19. Rix A, Lederle W, Siepmann M, Fokong S, Behrendt FF, Bzyl J, Grouls C, Kiessling F, Palmowski M: Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to antiangiogenic treatment. Eur J Radiol.
20. Montet X, Ntziachristos V, Grimm J, Weissleder R: Tomographic fluorescence mapping of tumor targets. Cancer Res 2005, 65:6330-6336.
21. Lederle W, Linde N, Heusel J, Bzyl J, Woenne EC, Zwick S, Skobe M, Kiessling F, Fusenig NE, Mueller MM: Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. Am J Pathol 2010, 176:981-994.
22. Reshef A, Shirvan A, Kselrod-Ballin A, Wall A, Ziv I: Small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med 2010, 51:837-840.
23. Wolters SL, Corsten MF, Reutelingsperger CP, Narula J, Hofstra L: Cardiovascular molecular imaging of apoptosis. Eur J Nucl Med Mol Imaging 2007, 34:S86-S98.
24. Neves AA, Brindle KM: Assessing responses to cancer therapy using molecular imaging. Biochim Biophys Acta 2006, 1766:242-261.
25. Hoebers FJ, Kartachova M, de BJ, van den Brekel MW, van TH, van HM, Rasch CR, Valdés Olmos RA, Verheij M: 99 mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging 2008, 35:509-518.
26. Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, Sandri M, Giusti A, Pesenti E, Terron A, Sbarbati A, Osculati F: Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005, 11:5827-5832.
27. Marzola P, Degrassi A, Calderan L, Farace P, Crescimanno C, Nicolato E, Giusti A, Pesenti E, Terron A, Sbarbati A, Abrams T, Murray L, Osculati F: In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 2004, 10:739-750.